BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy

Reuters

Mar 18, 2025

BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy

** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc ACOG.O with "buy" rating and $20 PT, a 251.5% upside to the stock's last close

** Says co's Alzheimer's disease drug Zunveyl, which is a "next-generation symptomatic therapy" has been shown to have a "very low rate of GI side effects (only 1-2%)" compared to 30-40% with existing cholinesterase inhibitors, and "eliminate sleep disturbances"

** Says co has a "finely tuned sales force" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl

** Co has a "considerable long-term promise" that is not reflected in its current stock price, which has been "range-bound" due to its relatively unknown status among US investors - brokerage

** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s

** Stock fell ~53% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520628128"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520628128\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520628128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-18 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520628128","market":"nz","top_or_hot":-1,"title":"BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy</title></head><body><p>** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc <span>ACOG.O</span> with \"buy\" rating and $20 PT, a 251.5% upside to the stock's last close</p><p>** Says co's Alzheimer's disease drug Zunveyl, which is a \"next-generation symptomatic therapy\" has been shown to have a \"very low rate of GI side effects (only 1-2%)\" compared to 30-40% with existing cholinesterase inhibitors, and \"eliminate sleep disturbances\"</p><p>** Says co has a \"finely tuned sales force\" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl</p><p>** Co has a \"considerable long-term promise\" that is not reflected in its current stock price, which has been \"range-bound\" due to its relatively unknown status among US investors - brokerage</p><p>** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s</p><p>** Stock fell ~53% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-18 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy</title></head><body><p>** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc <span>ACOG.O</span> with \"buy\" rating and $20 PT, a 251.5% upside to the stock's last close</p><p>** Says co's Alzheimer's disease drug Zunveyl, which is a \"next-generation symptomatic therapy\" has been shown to have a \"very low rate of GI side effects (only 1-2%)\" compared to 30-40% with existing cholinesterase inhibitors, and \"eliminate sleep disturbances\"</p><p>** Says co has a \"finely tuned sales force\" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl</p><p>** Co has a \"considerable long-term promise\" that is not reflected in its current stock price, which has been \"range-bound\" due to its relatively unknown status among US investors - brokerage</p><p>** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s</p><p>** Stock fell ~53% in 2024</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACOG","symbol_name":"ALPHA COGNITION INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nL4N3Q10QO:1","article_id":"2520628128","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520628128","pubTimestamp":1742295512,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc ACOG.O with \"buy\" rating and $20 PT, a 251.5% upside to the stock's last close** Says co's Alzheimer's disease drug Zunveyl, which is a \"next-generation symptomatic therapy\" has been shown to have a \"very low rate of GI side effects \" compared to 30-40% with existing cholinesterase inhibitors, and \"eliminate sleep disturbances\"** Says co has a \"finely tuned sales force\" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl** Co has a \"considerable long-term promise\" that is not reflected in its current stock price, which has been \"range-bound\" due to its relatively unknown status among US investors - brokerage** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s** Stock fell ~53% in 2024  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACOG":"ALPHA COGNITION INC","BK4139":"生物科技"},"translate_title":"巴斯-H.C。温赖特开始报道阿尔法认知，看好下一代阿尔茨海默病疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACOG":0.9},"content_text":"BUZZ-H.C. Wainwright starts coverage on Alpha Cognition, bullish on next-gen Alzheimer's therapy** Brokerage H.C. Wainwright starts coverage on drug developer Alpha Cognition Inc ACOG.O with \"buy\" rating and $20 PT, a 251.5% upside to the stock's last close** Says co's Alzheimer's disease drug Zunveyl, which is a \"next-generation symptomatic therapy\" has been shown to have a \"very low rate of GI side effects (only 1-2%)\" compared to 30-40% with existing cholinesterase inhibitors, and \"eliminate sleep disturbances\"** Says co has a \"finely tuned sales force\" that is expected to cover 80% of the long-term care market in the US, with 88% of physicians indicating they would prescribe Zunveyl** Co has a \"considerable long-term promise\" that is not reflected in its current stock price, which has been \"range-bound\" due to its relatively unknown status among US investors - brokerage** Estimates Zunveyl to generate $540 mln in peak annual sales in the US by the late 2030s** Stock fell ~53% in 2024 (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}